MedTrace Logo

Protective Effects of Oral L-Arginine CI-AKI

NCT02455960 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2015-05-28

No results posted yet for this study

Summary

This trial was performed to examine the efficacy of oral L-arginine for preventing CI-AKI in chronic kidney disease (CKD) patients.

Conditions

  • Contrast Induced AKI

Interventions

DIETARY_SUPPLEMENT

L-arginine

Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Phramongkutklao College of Medicine and Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-04-30
Completion
2016-05-31

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02455960 on ClinicalTrials.gov